CL2016000215A1 - Terapia y diagnóstico basado en proteínas de patología mediada por tau en enfermedad de alzheimer (divisional de sol. n° 679-14). - Google Patents

Terapia y diagnóstico basado en proteínas de patología mediada por tau en enfermedad de alzheimer (divisional de sol. n° 679-14).

Info

Publication number
CL2016000215A1
CL2016000215A1 CL2016000215A CL2016000215A CL2016000215A1 CL 2016000215 A1 CL2016000215 A1 CL 2016000215A1 CL 2016000215 A CL2016000215 A CL 2016000215A CL 2016000215 A CL2016000215 A CL 2016000215A CL 2016000215 A1 CL2016000215 A1 CL 2016000215A1
Authority
CL
Chile
Prior art keywords
tau
alzheimer
therapy
protein
disease
Prior art date
Application number
CL2016000215A
Other languages
English (en)
Inventor
Michal Noväk
Eva Kontsekovä
Norbert Zilka
Branislav Kovácech
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47216372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000215(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of CL2016000215A1 publication Critical patent/CL2016000215A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

<p>ANTICUERPO QUE SE UNE A UNO O MÁS EPÍTOPOS DE TAU; ÁCIDO NUCLEICO QUE CODIFICA EL DOMINIO DE UNIÓN O REGIÓN VARIABLE DE DICHO ANTICUERPO; VECTOR; CÉLULA HOSPEDADORA; LÍNEA CELULAR AISLADA O HIBRIDOMA; COMPOSICIÓN FARMACÉUTICA; DISPOSITIVO MÉDICO QUE COMPRENDE AL ANTICUERPO; Y USO PARA TRATAR ALZHEIMER O TAUOPATÍAS RELACIONADAS (DIVISIONAL DE SOL. N° 679-14).</p>
CL2016000215A 2011-09-19 2016-01-27 Terapia y diagnóstico basado en proteínas de patología mediada por tau en enfermedad de alzheimer (divisional de sol. n° 679-14). CL2016000215A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161536339P 2011-09-19 2011-09-19
US201261653115P 2012-05-30 2012-05-30

Publications (1)

Publication Number Publication Date
CL2016000215A1 true CL2016000215A1 (es) 2017-08-18

Family

ID=47216372

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2014000679A CL2014000679A1 (es) 2011-09-19 2014-03-19 Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada; y método para producir anticuerpo
CL2015001314A CL2015001314A1 (es) 2011-09-19 2015-05-14 Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; y uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada (div. sol. n° 679-14).
CL2016000215A CL2016000215A1 (es) 2011-09-19 2016-01-27 Terapia y diagnóstico basado en proteínas de patología mediada por tau en enfermedad de alzheimer (divisional de sol. n° 679-14).

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2014000679A CL2014000679A1 (es) 2011-09-19 2014-03-19 Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada; y método para producir anticuerpo
CL2015001314A CL2015001314A1 (es) 2011-09-19 2015-05-14 Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; y uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada (div. sol. n° 679-14).

Country Status (30)

Country Link
US (5) US9518101B2 (es)
EP (2) EP3275461A1 (es)
JP (7) JP6253583B2 (es)
KR (3) KR20210099167A (es)
CN (3) CN115417916A (es)
AU (3) AU2012311234B2 (es)
BR (1) BR112014006376B1 (es)
CA (1) CA2848346A1 (es)
CL (3) CL2014000679A1 (es)
CY (1) CY1119792T1 (es)
DK (1) DK2758433T3 (es)
ES (1) ES2656442T3 (es)
HK (1) HK1199459A1 (es)
HR (1) HRP20180083T8 (es)
HU (1) HUE036177T2 (es)
IL (4) IL231201B (es)
LT (1) LT2758433T (es)
ME (1) ME03008B (es)
MX (1) MX347505B (es)
MY (1) MY183989A (es)
PL (1) PL2758433T3 (es)
PT (1) PT2758433T (es)
RS (1) RS56852B1 (es)
RU (2) RU2018102103A (es)
SG (4) SG10201912964PA (es)
SI (1) SI2758433T1 (es)
TR (1) TR201800669T4 (es)
UA (2) UA123390C2 (es)
WO (1) WO2013041962A1 (es)
ZA (1) ZA201401333B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2826286C (en) * 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
EP2870176A4 (en) 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
US9567395B2 (en) 2012-08-16 2017-02-14 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
CN111569063A (zh) * 2013-11-27 2020-08-25 伊皮埃里安股份有限公司 治疗tau病变的方法
US10981953B2 (en) * 2013-12-26 2021-04-20 Toagosei Co, Ltd. Method for promoting expression of calreticulin, and synthetic peptide for use in method for promoting expression of calreticulin
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
EA036307B1 (ru) 2014-06-26 2020-10-23 Янссен Вэксинс Энд Превеншн Б.В. Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
KR102502356B1 (ko) 2014-09-30 2023-02-21 워싱턴 유니버시티 타우 (tau) 활동 계측
EP3221349B1 (en) 2014-11-19 2020-11-04 Axon Neuroscience SE Humanized tau antibodies in alzheimer's disease
JO3576B1 (ar) * 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
CN107849124B (zh) 2015-06-05 2021-09-24 基因泰克公司 抗tau抗体及使用方法
MX2017015817A (es) 2015-07-06 2018-04-10 Ucb Biopharma Sprl Anticuerpos de union a tau.
AU2016289753C1 (en) 2015-07-06 2021-08-05 UCB Biopharma SRL Tau-binding antibodies
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201518675D0 (en) * 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR20230070336A (ko) 2016-05-02 2023-05-22 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
EA201892417A1 (ru) * 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
KR101997319B1 (ko) 2016-06-21 2019-07-08 전남대학교산학협력단 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
FR3058143B1 (fr) * 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
CN117820467A (zh) 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CA3044679A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR102032314B1 (ko) * 2016-12-21 2019-10-16 주식회사 아델 변이된 타우 단백질 단편 및 이의 용도
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP7109467B2 (ja) * 2017-03-28 2022-07-29 ヤンセン ファッシンズ アンド プリベンション ベーフェー タウに特異的に結合する結合分子
WO2018195376A1 (en) * 2017-04-21 2018-10-25 Ohio University Peptide-based inhibitors of mark family proteins
AU2018263935A1 (en) 2017-05-02 2019-12-19 Prothena Biosciences Limited Antibodies recognizing tau
JP7029718B2 (ja) * 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
CA3076242A1 (en) 2017-10-02 2019-04-11 Blackthorn Therapeutics, Inc. Methods and systems for computer-generated predictive application of neuroimaging and gene expression mapping data
KR20200058480A (ko) 2017-10-16 2020-05-27 에자이 알앤드디 매니지먼트 가부시키가이샤 항-타우 항체 및 그의 용도
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
WO2019120527A1 (en) * 2017-12-20 2019-06-27 Michael Heneka Novel means and methods for treating neurodegenerative diseases
WO2019175735A1 (en) 2018-03-11 2019-09-19 Koorosh Shahpasand Conformation-independent antibodies against neurotoxic tau proteins
CA3095443A1 (en) * 2018-03-28 2019-10-03 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
RU2679059C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
US11085935B2 (en) 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation
AU2019262220A1 (en) * 2018-05-03 2020-11-12 Washington University Methods of diagnosing and treating based on site-specific tau phosphorylation
JP7102557B2 (ja) 2018-07-03 2022-07-19 エフ．ホフマン－ラ ロシュ アーゲー Ｔａｕ発現調節用オリゴヌクレオチド
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
EP3877410A4 (en) * 2018-11-08 2022-08-10 Prothena Biosciences Limited ANTIBODIES FOR DETECTING TAU
WO2020106598A1 (en) * 2018-11-19 2020-05-28 The Board Of Regents Of The University Of Texas System Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies
SG11202106717PA (en) * 2019-02-08 2021-07-29 Prothena Biosciences Ltd Antibodies recognizing tau
JP2022524588A (ja) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
US20220177558A1 (en) * 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
KR102633666B1 (ko) * 2019-05-31 2024-02-06 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법
GB201909393D0 (en) 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
WO2021024209A1 (en) * 2019-08-06 2021-02-11 Aprinoia Therapeutics Inc. Antibodies that bind to pathological tau species and uses thereof
AU2020331020A1 (en) * 2019-08-13 2022-03-03 Washington University Methods to detect MTBR tau isoforms and use thereof
US20220275038A1 (en) * 2019-08-15 2022-09-01 Tokyo Medical University Clsp derivative incapable of being affected by clsp inhibiting substance, and clsp activity enhancing/protecting agent
MX2022002852A (es) 2019-09-09 2022-03-25 Axon Neuroscience Se Biomarcadores y tratamientos de la enfermedad de alzheimer y deterioro cognitivo leve.
IL270800A (en) * 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
CN110841059A (zh) * 2019-12-03 2020-02-28 南通大学 老年性痴呆小鼠模型的制备方法
KR20220137674A (ko) * 2020-02-05 2022-10-12 스미토모 파마 가부시키가이샤 타우병증 및 인지증 관련 질환의 판정약 및 판정 방법
EP4252243A2 (en) 2020-11-30 2023-10-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
EP4291234A1 (en) * 2021-02-14 2023-12-20 Prothena Biosciences Limited Methods of using antibodies recognizing tau
JP2024509683A (ja) * 2021-02-19 2024-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｐｔ２１７ ｔａｕ抗体
CN113430230A (zh) * 2021-06-24 2021-09-24 南通大学 tau截断体蛋白在诱导tau病理聚集中的应用
WO2023060276A1 (en) * 2021-10-08 2023-04-13 Arbele Limited Compositions and methods for detecting cadherin-17 protein
CN113861441A (zh) * 2021-10-28 2021-12-31 南开大学 一种tau蛋白特异的纳米分子伴侣的制备方法及其在抑制tau聚集中的应用
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN116554342A (zh) * 2022-01-29 2023-08-08 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
ATE386115T1 (de) * 1991-12-06 2008-03-15 Max Planck Gesellschaft Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
JPH09501936A (ja) 1993-08-26 1997-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
EP0791067B1 (en) * 1994-10-28 2008-12-17 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Protein kinase npk-110
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5643207A (en) 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DK0859959T3 (da) 1995-11-10 2003-11-24 Elan Corp Plc Peptider, som øger transporten over væv, og fremgangsmåder til identificering og anvendelse af disse
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU1631700A (en) 1998-11-23 2000-06-13 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
US6198966B1 (en) 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
JP3383618B2 (ja) 1999-08-18 2003-03-04 松下電器産業株式会社 移動体通信端末装置及び受信強度検出方法
WO2001018544A1 (en) * 1999-09-09 2001-03-15 Mcgill University Diagnosis, prognosis and treatment of trinucleotide repeat-associated diseases and intranuclear inclusions-associated diseases
JP2003508788A (ja) * 1999-09-09 2003-03-04 マックス−プランク−ゲゼルシャフト ツール フォルデルング デル ヴィッセンシャフテン エー．ファウ． ペアードヘリカルフィラメントの核形成のための最小タウペプチド
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
DE50111493D1 (de) 2001-09-03 2007-01-04 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Antigen-Mimotope und Vakzine gegen Krebserkrankungen
TWI226905B (en) 2001-10-19 2005-01-21 Bioware Technology Co Ltd Low pressure-accelerated particle gene gun
CN100572392C (zh) 2002-07-12 2009-12-23 阿克松神经科学研究和发展股份有限公司 截短tau蛋白
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
EP1516930A1 (en) 2003-09-16 2005-03-23 Georg-August Universität Göttingen Cellular model of tauopathies for lead identification and drug discovery
US20050142609A1 (en) 2003-10-08 2005-06-30 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
US8377875B2 (en) 2007-01-11 2013-02-19 Ramot At Tel-Aviv University Ltd. Therapeutics based on tau/microtubule dynamics
TR201802286T4 (tr) * 2007-04-20 2018-03-21 The Chemo Sero Therapeutic Res Institute Peptidle bağışıklık yanıtının arttırılması için yöntem.
WO2009000520A1 (en) 2007-06-25 2008-12-31 Universität Duisburg-Essen Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
CN102596221B (zh) 2009-06-10 2019-06-04 纽约大学 病理tau蛋白的免疫靶向
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
JP6124591B2 (ja) * 2009-08-28 2017-05-10 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム タウオリゴマーに結合する抗体
WO2011053565A2 (en) 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
CN102791725A (zh) * 2009-11-06 2012-11-21 J.大卫格莱斯顿学会 调节tau水平的方法和组合物
EP2905332B1 (en) * 2009-11-19 2018-09-12 Solis BioDyne OÜ Compositions for increasing polypeptide stability and activity, and related methods
CL2010000019A1 (es) 2010-01-11 2010-06-11 Univ Chile Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.

Also Published As

Publication number Publication date
SI2758433T1 (en) 2018-02-28
RU2645259C2 (ru) 2018-02-19
DK2758433T3 (en) 2018-01-15
EP2758433A1 (en) 2014-07-30
PT2758433T (pt) 2018-01-19
US20170260263A1 (en) 2017-09-14
JP2018117631A (ja) 2018-08-02
IL259775A (en) 2018-07-31
CL2015001314A1 (es) 2015-09-21
US20180282401A1 (en) 2018-10-04
ES2656442T3 (es) 2018-02-27
IL231201B (en) 2018-06-28
UA115657C2 (uk) 2017-12-11
US20150050215A1 (en) 2015-02-19
US11098106B2 (en) 2021-08-24
US9828421B2 (en) 2017-11-28
AU2017272259A1 (en) 2018-01-04
HUE036177T2 (hu) 2018-06-28
SG10201912955PA (en) 2020-02-27
LT2758433T (lt) 2018-02-12
PL2758433T3 (pl) 2018-06-29
CN109265543A (zh) 2019-01-25
JP6499345B2 (ja) 2019-04-10
IL231201A0 (en) 2014-04-30
JP6950981B2 (ja) 2021-10-20
CN104185640A (zh) 2014-12-03
HRP20180083T8 (hr) 2018-07-27
IL259775B (en) 2020-05-31
EP3275461A1 (en) 2018-01-31
AU2017272259B2 (en) 2019-11-14
RS56852B1 (sr) 2018-04-30
SG10201912964PA (en) 2020-02-27
BR112014006376B1 (pt) 2021-07-27
US9845352B2 (en) 2017-12-19
JP2017042172A (ja) 2017-03-02
CY1119792T1 (el) 2018-06-27
CA2848346A1 (en) 2013-03-28
ME03008B (me) 2018-10-20
MX2014003357A (es) 2015-03-20
AU2020200624B2 (en) 2021-12-23
BR112014006376A2 (pt) 2017-06-13
EP2758433B1 (en) 2017-10-18
HK1199459A1 (en) 2015-07-03
AU2012311234A1 (en) 2014-05-01
JP6637124B2 (ja) 2020-01-29
KR102285743B1 (ko) 2021-08-06
CN109265543B (zh) 2022-04-26
CN104185640B (zh) 2018-07-20
RU2018102103A3 (es) 2021-05-31
RU2018102103A (ru) 2019-02-21
AU2020200624A1 (en) 2020-02-20
JP6360869B2 (ja) 2018-07-18
KR102130439B1 (ko) 2020-07-07
SG11201400125RA (en) 2014-03-28
JP6286590B2 (ja) 2018-02-28
IL287794A (en) 2022-01-01
HRP20180083T1 (hr) 2018-02-23
WO2013041962A1 (en) 2013-03-28
CN115417916A (zh) 2022-12-02
MX347505B (es) 2017-04-28
RU2014115481A (ru) 2015-10-27
US20220010004A1 (en) 2022-01-13
US20170145082A1 (en) 2017-05-25
SG10201703771WA (en) 2017-06-29
KR20210099167A (ko) 2021-08-11
JP7182316B2 (ja) 2022-12-02
JP2022031631A (ja) 2022-02-22
CL2014000679A1 (es) 2014-11-21
MY183989A (en) 2021-03-17
ZA201401333B (en) 2015-09-30
US9518101B2 (en) 2016-12-13
JP2020072675A (ja) 2020-05-14
JP2014530597A (ja) 2014-11-20
IL274440B (en) 2021-12-01
IL274440A (en) 2020-06-30
JP2017093470A (ja) 2017-06-01
JP2018183160A (ja) 2018-11-22
AU2012311234B2 (en) 2017-09-28
UA123390C2 (uk) 2021-03-31
KR20200084362A (ko) 2020-07-10
KR20140063853A (ko) 2014-05-27
AU2020200624A9 (en) 2021-12-23
JP6253583B2 (ja) 2017-12-27
TR201800669T4 (tr) 2018-03-21

Similar Documents

Publication Publication Date Title
CL2016000215A1 (es) Terapia y diagnóstico basado en proteínas de patología mediada por tau en enfermedad de alzheimer (divisional de sol. n° 679-14).
AR085198A1 (es) Composicion farmaceutica
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
CL2017002345A1 (es) Un nuevo complejo que comprende un péptido de penetración celular, una molécula cargo y un agonista peptídico de tlr
AR092779A1 (es) Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
PE20170782A1 (es) Anticuerpos frente a cd73 y usos de los mismos
WO2014031694A3 (en) Anti-tau antibodies and methods of making and using in treatment of tauopathies
BR112017008165B8 (pt) anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
AR085591A1 (es) Anticuerpos del antigeno carcinoembrionario humano (cea)
AR092818A1 (es) Anticuerpo tau humanizado
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
MA34926B1 (fr) Composition effervescente sous forme solide utilisable dans des applications vaginales pour le traitement d&#39;infections vaginales
UA115540C2 (uk) Антитіло до il-36r
UA113609C2 (xx) Антигензв&#39;язуючий білок, який зв&#39;язує людський il-23
CL2012002415A1 (es) Anticuerpo monoclonal aislado que se une al inhibidor de la via del factor tisular humano (tfpi); composicion farmacéutica que comprende dicho anticuerpo; procedimientos para tratar deficiencias o defectos genéticos o adquiridos en la coagulación; molecula de acido nucleico que codifica el anticuerpo; vector y célula huesped.
ECSP11011297A (es) Proteinas ligadoras il-17
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
CL2013002811A1 (es) Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion.
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201390813A1 (ru) Антитела и их применение
UA111340C2 (uk) Антитіло, яке специфічно зв&#39;язується з tnf-альфа людини
EA201400964A1 (ru) Cx3cr1-связывающие полипептиды
AR084627A1 (es) Formulacion farmaceutica que comprende una droga biofarmaceutica
BR112016013185A2 (pt) Inibidores de cinase relacionada à tropomiosina (trk)